New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
07:41 EDTPCYCPharmacyclics recent pullback a buying opportunity, says Goldman
Goldman views the recent pullback in Pharmacyclics as a buying opportunity and sees multiple catalysts that include Ph. 3 Resonate data by the end of January, expected FDA approval of Imbuvca for r/r CLL, and a clean label for r/r CLL. Shares are Buy rated with a $165 price target.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use